192 related articles for article (PubMed ID: 33878963)
21. RIPK3 is a novel prognostic marker for lower grade glioma and further enriches IDH mutational status subgrouping.
Vergara GA; Eugenio GC; Malheiros SMF; Victor EDS; Weinlich R
J Neurooncol; 2020 May; 147(3):587-594. PubMed ID: 32222932
[TBL] [Abstract][Full Text] [Related]
22. Identification of a Two-m6A RNA Methylation Regulator Risk Signature as an Independent Prognostic Biomarker in Papillary Renal Cell Carcinoma by Bioinformatic Analysis.
Yang F; Zhao G; Ge L; Song Y; Hong K; Zhang H; Liu C; Hong P; Ma L
Biomed Res Int; 2021; 2021():4582082. PubMed ID: 33628782
[TBL] [Abstract][Full Text] [Related]
23. A Novel 10-Gene Signature Predicts Poor Prognosis in Low Grade Glioma.
Liu W; Zou J; Ren R; Liu J; Zhang G; Wang M
Technol Cancer Res Treat; 2021; 20():1533033821992084. PubMed ID: 33550903
[TBL] [Abstract][Full Text] [Related]
24. Bioinformatics profiling integrating a four immune-related long non-coding RNAs signature as a prognostic model for papillary renal cell carcinoma.
Liu Y; Gou X; Wei Z; Yu H; Zhou X; Li X
Aging (Albany NY); 2020 Jul; 12(15):15359-15373. PubMed ID: 32716909
[TBL] [Abstract][Full Text] [Related]
25. Identification and validation of ubiquitin-proteasome system related genes as a prognostic signature for papillary renal cell carcinoma.
Zhang X; Liu X; Xiong R; An HX
Aging (Albany NY); 2022 Nov; 14(23):9599-9616. PubMed ID: 36385010
[TBL] [Abstract][Full Text] [Related]
26. EFNA1 is a potential key gene that correlates with immune infiltration in low-grade glioma.
Hao YP; Wang WY; Qiao Q; Li G
Medicine (Baltimore); 2021 Jun; 100(22):e26188. PubMed ID: 34087884
[TBL] [Abstract][Full Text] [Related]
27. Integrated Phenotypic/Genotypic Analysis of Papillary Renal Cell Carcinoma Subtypes: Identification of Prognostic Markers, Cancer-related Pathways, and Implications for Therapy.
Saleeb RM; Plant P; Tawedrous E; Krizova A; Brimo F; Evans AJ; Wala SJ; Bartlett J; Ding Q; Boles D; Rotando F; Farag M; Yousef GM
Eur Urol Focus; 2018 Sep; 4(5):740-748. PubMed ID: 28753789
[TBL] [Abstract][Full Text] [Related]
28. Non-SMC condensin I complex subunit D2 (NCAPD2) reveals its prognostic and immunologic features in human cancers.
Dong X; Liu T; Li Z; Zhai Y
Aging (Albany NY); 2023 Jul; 15(14):7237-7257. PubMed ID: 37498296
[TBL] [Abstract][Full Text] [Related]
29. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
30. Identification of Critical m
Zheng J; Wang X; Qiu Y; Wang M; Yu H; Zhou Z; Wu Z; Jiang X
Biomed Res Int; 2021; 2021():9959212. PubMed ID: 34212046
[TBL] [Abstract][Full Text] [Related]
31. Expression of CD40 Correlates Negatively with Overall and Progression-Free Survival of Low- and High-Grade Gliomas.
Werner JM; Kuhl S; Ulrich K; Krischek B; Stavrinou P; Goldbrunner R; Timmer M
World Neurosurg; 2019 Oct; 130():e17-e25. PubMed ID: 31125770
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathological, genetic, ultrastructural characterizations and prognostic factors of papillary renal cell carcinoma: new diagnostic and prognostic information.
Yu W; Zhang W; Jiang Y; Wang Y; Li Y; Wang J; Sun L; Ran W; Li H
Acta Histochem; 2013 Jun; 115(5):452-9. PubMed ID: 23219441
[TBL] [Abstract][Full Text] [Related]
33. Expression Profiles and Clinical Significance of MicroRNAs in Papillary Renal Cell Carcinoma: A STROBE-Compliant Observational Study.
Ge YZ; Xu LW; Xu Z; Wu R; Xin H; Zhu M; Lu TZ; Geng LG; Liu H; Zhou CC; Yu P; Zhao YC; Hu ZK; Zhao Y; Zhou LH; Wu JP; Li WC; Zhu JG; Jia RP
Medicine (Baltimore); 2015 Apr; 94(16):e767. PubMed ID: 25906110
[TBL] [Abstract][Full Text] [Related]
34. High CENPA expression in papillary renal cell carcinoma tissues is associated with poor prognosis.
Li J; Li Q; Yuan Y; Xie Y; Zhang Y; Zhang R
BMC Urol; 2022 Sep; 22(1):157. PubMed ID: 36163007
[TBL] [Abstract][Full Text] [Related]
35. Systematic pan-cancer analyses of the potential function of the Golgi scaffold protein PAQR3.
Ling ZN; Hong LL; Wu J; Ling ZQ
Sci Rep; 2024 Feb; 14(1):3030. PubMed ID: 38321173
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Value of Immune-Related lncRNA SBF2-AS1 in Diffuse Lower-Grade Glioma.
Zhang Q; Liu XJ; Li Y; Ying XW; Chen L
Technol Cancer Res Treat; 2021; 20():15330338211011966. PubMed ID: 34159865
[TBL] [Abstract][Full Text] [Related]
37. CD133 in brain tumor: the prognostic factor.
Li B; McCrudden CM; Yuen HF; Xi X; Lyu P; Chan KW; Zhang SD; Kwok HF
Oncotarget; 2017 Feb; 8(7):11144-11159. PubMed ID: 28055976
[TBL] [Abstract][Full Text] [Related]
38. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
Front Immunol; 2022; 13():899710. PubMed ID: 35677036
[TBL] [Abstract][Full Text] [Related]
39. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
[TBL] [Abstract][Full Text] [Related]
40. Integrative analysis of DNA methylation and gene expression in papillary renal cell carcinoma.
Singh NP; Vinod PK
Mol Genet Genomics; 2020 May; 295(3):807-824. PubMed ID: 32185457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
